IDEXX Laboratories Inc (IDXX) (Q3 2026) Earnings Call Highlights: Raised Outlook, Record ...

Negative Points

• US same-store clinical visits declined an estimated 1.8% in the quarter, reflecting ongoing pressure on clinic traffic.

• Puppy and kitten adoption levels remain muted, and the macro environment continues to be challenging, impacting overall visit trends.

• The CoVet acquisition is expected to be dilutive to near-term EPS, with approximately $0.13 per share dilution in 2026 and a 30 basis point negative impact on operating margin.

• Foreign exchange is expected to create a headwind of approximately 70 basis points on fourth-quarter revenue growth.

• Global Rapid Assay revenues increased only 1% organically in the quarter, sustaining modest growth.

Q & A Highlights

Q: Chris Schott of JPMorgan asked how IDEXX lifted its full-year organic growth outlook from roughly 8% to nearly 10% despite a US visit environment that hasn't materially improved and whether new platforms, sales force expansion, or visits simply being a poor proxy are driving it. He also asked about puppy versus older-dog visit trends. A: CEO Mike Erickson credited volume-led growth from innovations (inVue Dx, Cancer Dx, Catalyst proBNP, and even the two-year-old Pancreatic Lipase), record Q3 instrument placements, strong lab new-customer gains, and higher-quality visits from positive pet demographics, stressing that growth does not depend on positive visits. CFO Andrew Emerson added that the initial guide's high end has already been exceeded, and noted the aging cohort continues to add growth while puppy/kitten adoption remains muted amid a challenging macro but pets living longer and favorable breed mix are long-term tailwinds.

Q: Jon Block of Stifel noted inVue Dx is at roughly 11,000 units since launch more than half the 20,000 five-year goal in about two years and asked whether the long-term placement assumption has changed. A: Erickson said IDEXX is on track to exceed both the 5,500 placement goal for 2026 and the 20,000 five-year goal, with nearly half of Q3 placements international. He highlighted menu expansion (nucleated RBCs and eccentricytes added to blood morphology) and broad North American FNA availability, noting early FNA customers are evaluating twice as many masses.

Q: Jon Block asked whether the CoVet acquisition changes the 50100 basis points of annual operating margin expansion in the long-range plan, and whether dilution will persist into the first two to three quarters of 2027. A: Emerson said the roughly 30 basis points of CoVet impact spans Q3 and Q4 and is factored into the profile, but IDEXX is still delivering on its long-term margin algorithm and raised revenue and EPS guidance. He expects to grow total company revenue in line with the 50100 basis point annual margin expansion over the next 12 months, building CoVet's margins as integration progresses while capturing multiplier benefits in diagnostic utilization.

Q: Erin Wright of Morgan Stanley asked how much macro sensitivity is baked into guidance, whether demand shifted during the quarter, and how reference labs achieved another double-digit quarter market share gains versus greater utilization. A: Emerson said macro trends have been relatively consistent and in line with prior guidance, with quarter-to-quarter choppiness captured in the range; the focus is on visit quality broader and more frequent diagnostic use. Erickson attributed lab growth to long-term investments in networks, technology, and innovation, noting over 20% of Cancer Dx runs come from customers not primarily using IDEXX labs, creating conversion opportunities, plus additions like Taenia to the Fecal Dx panel.

Q: Matt Dellatorre of Goldman Sachs asked what drove strong inVue Dx placements and how clinics are using the product across blood morphology and FNA, plus what will be disclosed at the VMX event regarding MultiQ Dx and launch timing. A: Erickson said inVue Dx addresses cytology a manual, technique-sensitive category practiced in virtually every clinic for over 100 years by eliminating the slide, and IDEXX keeps expanding the menu (over half a dozen blood morphology additions this year). International accounted for nearly half of placements. On MultiQ Dx, he declined to provide details ahead of the January 18 investor event at VMX in Orlando.

Q: Steven Dechert of KeyBanc asked how many of the clinics that have ordered Cancer Dx are recurring customers. A: Erickson said over 14,000 customers have ordered and run Cancer Dx, though IDEXX doesn't break out recurring versus one-time users. He emphasized strong momentum and multiplier benefits, with 70% of Cancer Dx runs accompanying a broader blood work panel, and called it still early days with significant opportunity as the panel expands.

Q: Daniel Clark of Leerink asked how inVue Dx revenue per analyzer already within the $3,500$5,500 annual range might trend over time given significant unmet need. A: Erickson said IDEXX is comfortably in the range, which encompasses ear cytology, blood morphology, and FNA across various practice sizes as availability broadens internationally. He expects FNA rollout to drive additional upside, noting roughly 100 million cytology tests are still done manually worldwide, leaving a long runway.

Q: Daniel Clark followed up on incremental inVue Dx placement opportunity, noting strong international momentum versus a more stable US, and asked where each stands in terms of innings. A: Erickson said IDEXX is in full worldwide launch mode for inVue Dx and sees meaningful headroom to continue placing instruments globally.

Q: Navann Ty of BNP Paribas asked whether diagnostics pricing will remain resilient versus animal health pharma, where a therapeutic market leader has announced pricing action. A: Erickson declined to comment on pharma pricing but said diagnostics is competitive and IDEXX prices to the value it creates, with transparent pricing contributions to growth. He pointed to the affordable Cancer Dx panel (as low as $15 in the US with most blood work) as a bold stance on accessible screening that drives volume citing a corporate group and an independent practice seeing higher wellness blood work inclusion. Emerson added that pricing expectations have been consistent since initial guidance, with IDEXX focused on expanding the sector through volume rather than maximizing price.

Q: Navann Ty also asked for early feedback on the mast cell tumor addition launched in September. A: Erickson said feedback is very positive, though the launch is early. Customers welcome Cancer Dx becoming a multi-cancer panel, and mast cell tumors among the most common canine cancers and frequently missed, especially in long-coated dogs connect naturally to inVue Dx FNA as a next step after a positive result. He noted high excitement for the upcoming hemangiosarcoma addition.

For the complete transcript of the earnings call, please refer to the full earnings call transcript .